• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ACW

Actinogen Medical Limited

2.38% ! 4.3¢
Market Cap $153.6M  !
Healthcare Biotechnology
Add to My Watchlist

Actinogen Medical Limited, formerly Actinogen Limited, is a clinical-stage biotechnology... Actinogen Medical Limited, formerly Actinogen Limited, is a clinical-stage biotechnology company. The Company focuses on the treatment of Alzheimer's disease and age-related neurodegenerative diseases. The Company is engaged in treating cognitive impairment in chronic neurodegenerative diseases through the inhibition of cortisol production. The Company's Xanamem is a drug under development for the treatment of Alzheimer's disease, which is designed to block the production of cortisol in the brain. Xanamem's mechanism of action is to block the activity of a specific enzyme in the brain, the 11B-HSD1 enzyme. It focuses on Xanamem in the clinical areas, including Diabetes-Cognitive dysfunction, Cognitive dysfunction in Parkinson's Disease, Post Traumatic Stress Disorder (PTSD), Cognitive dysfunction in schizophrenia and depression, and Cardiovascular disease-Post myocardial infarction. It focuses on Phase II XanADu efficacy and safety study with mild Alzheimer's disease patients.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
ACW
ACW Investor Briefing Sydney 		20/04/18 46 10K
20/04/18 Last post  Oupa Comments Created with Sketch.  46  Views Created with Sketch.  10K 
ACW
Ann: Cleansing Notice 		19/04/18 6 1.0K
19/04/18 Last post  djwally Comments Created with Sketch.  6  Views Created with Sketch.  1.0K 
ACW
Ann: Appendix 3B-Exercise of Options 		18/04/18 0 168
18/04/18 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  168 
ACW
Ann: New Analyst Report on Actinogen Medical 		11/04/18 2 752
11/04/18 Last post  NZ Trader Comments Created with Sketch.  2  Views Created with Sketch.  752 
ACW
Share price 		05/04/18 18 3.6K
05/04/18 Last post  Hill Billy 55 Comments Created with Sketch.  18  Views Created with Sketch.  3.6K 
ACW
Ann: Appendix 3B 		03/04/18 0 166
03/04/18 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  166 
ACW
ACW in Fairfax Media 		28/03/18 6 2.5K
28/03/18 Last post  Owl vs Fox Comments Created with Sketch.  6  Views Created with Sketch.  2.5K 
ACW
Ann: Invitation to Investor Briefing 		26/03/18 48 14K
26/03/18 Last post  Wasabibarako Comments Created with Sketch.  48  Views Created with Sketch.  14K 

See All Discussions arrow Created with Sketch.

Featured News

NEWS Want to reach millions of investors? Get in touch
right-arrow Created with Sketch.
NEWS Read the Latest ASX News here on HotCopper
right-arrow Created with Sketch.
NEWS Watch the Latest Video Interviews here on HotCopper
right-arrow Created with Sketch.

Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
Start T rading
Last
4.3¢ 		Change
0.001(2.38%) 		Mkt cap ! $153.6M
Open High Low Volume
4.3¢ 4.4¢ 4.2¢ 680.2K

Buyers (Bids)

Vol. Price($)
33019 4.3¢
 

Sellers (Offers)

Price($) Vol.
4.4¢ 534398
Last trade - 16.10pm 28/08/2026 (20 minute delay) ?
ACW (ASX) Chart

Top Stories

4DMedical posts FY26 revenue growth as commercial deployment ramps up

4DMedical reports 21% FY26 revenue growth as CT:VQ gains commercial adoption, global regulatory approvals and major healthcare partnerships.
Capital Compass: Askari Metals advances Ethiopia strategy as permitting remains key focus Askari Metals Executive Director Gino D’Anna discusses the company’s Ethiopia strategy, permitting progress, and broader portfolio ambitions.
Memphasys receives early Thai FDA Felix approval Memphasys' Felix System has received earlier than anticipated approval from the Thai Food and Drug Administration.
Civmec earnings: Profit climbs as $1.4b order book backs FY27 growth Civmec has delivered FY26 revenue growth of 11.4% and a 22.5% rise in profit, with a $1.4 billion order book supporting its FY27 outlook.
Imricor Med and Philips launch commercial iMR lab solution Imricor Medical Systems has launched a new Interventional MR (iMR) lab solution in collaboration with Dutch company Royal Philips.

Featured News

NEWS Want to reach millions of investors? Get in touch
right-arrow Created with Sketch.
NEWS Watch the Latest Video Interviews here on HotCopper
right-arrow Created with Sketch.
NEWS Read the Latest ASX News here on HotCopper
right-arrow Created with Sketch.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.